March 21, 2024

The U.S. Food and Drug Administration (FDA) published a paper March 15, to update the public about intra-agency activities to oversee artificial intelligence (AI)-enabled healthcare technologies. The paper summarizes priorities shared across the biologics, drugs and medical devices domains of FDA jurisdiction.

Four general focus areas are discussed: fostering collaboration with stakeholders; developing appropriate regulatory approaches; promoting development of standards and best practices; and supporting research on performance evaluation. Moving forward, the FDA intends to evolve its own regulatory approaches with the continued progression of AI tools.

For more information about various American College of Radiology®(ACR®) AI-specific initiatives, visit the ACR Data Science Institute®. For more information about FDA oversight and digital health policy, contact Michael Peters, ACR Senior Government Affairs Director.


Related ACR News

  • Focus on Scope: Latest Status of State Healthcare-Related Bills

    Overview of status of several bills in this year’s state legislative sessions related to scope of practice.

    Read more
  • Participate in the Healthcare AI Challenge at ACR 2025

    Call for ACR 2025 attendees to participate in healthcare AI challenge at the upcoming meeting.

    Read more
  • Supreme Court Hears Oral Arguments in Kennedy vs. Braidwood Case

    ACR is monitoring the Kennedy vs. Braidwood Management case, which could potentially affect full insurance coverage of at least some cancer screening exams.

    Read more